Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




May
06
Today In Oncology
Advanced CKM Syndrome Associated With Greater Cancer Risk
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
Adjuvant Hepatic Arterial Infusion After Surgery for Four or More Colorectal Liver Metastases
Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo